NCT02757534

Domperidone for Chronic Nausea and Vomiting

Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Yehudith Assouline-Dayan · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to provide oral domperidone to patients with gastroparesis, between the ages of 18 and 60 years of age, who have failed standard treatment. Standard therapy at the University of Iowa is eating blended foods, liquid diet, Eryped syrup (125 mg TID) 30 minutes before meals, or reglan (20 mg BID).

Detailed description

This is a compassionate use research study for a non-FDA approved drug. We are inviting patients to participate in this research study because they have nausea and vomiting related to gastroparesis and have failed standard therapy. The purpose of this research study is to prescribe patients with domperidone. Domperidone is considered investigational, which means that it has not been approved by the FDA.

Conditions

• Gastroparesis

Interventions

Type	Name	Description
DRUG	Domperidone	The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.

Timeline

• First posted: 2016-05-02
• Last updated: 2020-05-05

Locations

1 site across 1 country: United States